213 related articles for article (PubMed ID: 26873344)
1. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
2. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
[TBL] [Abstract][Full Text] [Related]
3. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
5. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
6. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
7. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
Ni D; Liu D; Zhang J; Lu S
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
[TBL] [Abstract][Full Text] [Related]
8. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin and PI3K Signaling in
Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V
Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH
Zhang M; Jang H; Gaponenko V; Nussinov R
Biophys J; 2017 Nov; 113(9):1956-1967. PubMed ID: 29117520
[TBL] [Abstract][Full Text] [Related]
11. Regulation of K-Ras4B Membrane Binding by Calmodulin.
Sperlich B; Kapoor S; Waldmann H; Winter R; Weise K
Biophys J; 2016 Jul; 111(1):113-22. PubMed ID: 27410739
[TBL] [Abstract][Full Text] [Related]
12. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.
Nussinov R; Tsai CJ; Muratcioglu S; Jang H; Gursoy A; Keskin O
Expert Rev Proteomics; 2015; 12(6):669-82. PubMed ID: 26496174
[TBL] [Abstract][Full Text] [Related]
13. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
14. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S; Jang H; Gu S; Zhang J; Nussinov R
Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
[TBL] [Abstract][Full Text] [Related]
15. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
[TBL] [Abstract][Full Text] [Related]
16. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.
Abraham SJ; Nolet RP; Calvert RJ; Anderson LM; Gaponenko V
Biochemistry; 2009 Aug; 48(32):7575-83. PubMed ID: 19583261
[TBL] [Abstract][Full Text] [Related]
17. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
18. The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin.
Jang H; Banerjee A; Marcus K; Makowski L; Mattos C; Gaponenko V; Nussinov R
Structure; 2019 Nov; 27(11):1647-1659.e4. PubMed ID: 31495533
[TBL] [Abstract][Full Text] [Related]
19. K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract][Full Text] [Related]
20. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.
Alvarez-Moya B; López-Alcalá C; Drosten M; Bachs O; Agell N
Oncogene; 2010 Nov; 29(44):5911-22. PubMed ID: 20802526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]